Defining the frontiers between antifungal resistance, tolerance and the concept of persistence. by Delarze, E. & Sanglard, D.
D
t
E
I
a
K
A
T
P
1
t
i
c
a
p
d
d
(
i
h
i
y
a
i
p
r
s
S
a
h
1Drug Resistance Updates 23 (2015) 12–19
Contents lists available at ScienceDirect
Drug  Resistance Updates
jo ur nal homep age: www.elsev ier .com/ locate /drup
eﬁning  the  frontiers  between  antifungal  resistance,  tolerance  and
he  concept  of  persistence
ric  Delarze,  Dominique  Sanglard ∗
nstitute of Microbiology, University Hospital Lausanne and University Hospital Center, Rue de Bugnon 48, CH-1011 Lausanne, Switzerland
 r  t  i  c  l e  i  n  f  o
eywords:
ntifungal resistance
olerance
ersistence
a  b  s  t  r  a  c  t
A  restricted  number  of  antifungal  agents  are  available  for the  therapy  of  fungal  diseases.  With  the  intro-
duction  of  epidemiological  cut-off  values  for each  agent  in  important  fungal  pathogens  based  on  the
distribution  of minimal  inhibitory  concentration  (MIC),  the distinction  between  wild type  and  drug-
resistant  populations  has  been  facilitated.  Antifungal  resistance  has been  described  for  all  currently
available  antifungal  agents  in several  pathogens  and  most  of the  associated  resistance  mechanisms  have
been deciphered  at the  molecular  level.  Clinical  breakpoints  for some  agents  have  been proposed  and
can  have  predictive  value  for the  success  or failure  of  therapy.  Tolerance  to  antifungals  has  been  a much
more  ignored  area.  By deﬁnition,  tolerance  operates  at antifungal  concentrations  above  individual  intrin-
sic inhibitory  values.  Important  is  that  tolerance  to  antifungal  agents  favours  the  emergence  of  persister
cells,  which  are able  to survive  antifungal  therapy  and  can cause  relapses.  Here  we  will review  the  cur-
rent  knowledge  on  antifungal  tolerance,  its potential  mechanisms  and  also  evaluate  the  role  of  antifungal
tolerance  in the  efﬁcacy  of drug  treatments.
©  2015  Elsevier  Ltd.  All  rights  reserved.. Introduction
Resistance of microbes to anti-infectives is an increasing threat
o human health and has a signiﬁcant socio-economic impact
n national health systems. However, the actions undertaken to
ounteract drug resistance remain largely insufﬁcient. Bacterial
ntibiotic resistance is a dominant research area due the high
revalence of hospital bacterial infections. Resistance to antifungal
rugs has received less attention, although the occurrence of fungal
iseases is far from negligible. These diseases range from superﬁcial
oral or genito-urinary tract thrushes) to life-threatening systemic
nfections and cause high levels of morbidity and mortality. It
as been reported that about 1.7 billion people worldwide are
nfected with pathogenic fungi, from which 1.5 million die every
ear (Brown et al., 2012). While the majority of pathogenic fungi
re opportunistic pathogens, they become deadly pathogens in
mmunocompromised patients. The increased use of immunosup-
ressive therapies for cancer and organ transplants has resulted in
ising incidence of invasive fungal diseases. The number of fungal
epsis has risen by 207% between 1979 and 2000 in the United
tates and disseminated systemic candidiasis is associated with
larmingly high rates of mortality of up to 50% (Martin et al., 2003).
∗ Corresponding author. Tel.: +41 21 3144083.
E-mail address: Dominique.sanglard@chuv.ch (D. Sanglard).
ttp://dx.doi.org/10.1016/j.drup.2015.10.001
368-7646/© 2015 Elsevier Ltd. All rights reserved.Candida albicans remains a major fungal pathogen in invasive dis-
eases and is followed by several Candida spp. including C. glabrata, C.
parapsilosis and C. tropicalis (Arendrup, 2010). Among ﬁlamentous
fungi, Aspergilli spp. are predominant and especially A. fumigatus.
This fungal species is a major cause of death in acute leukemia
patients. Approximately 30% of bone marrow or organ transplants
will develop invasive aspergillosis with poor prognosis (Richardson
and Lass-Flörl, 2008).
A restricted number of chemical classes are currently in clinical
use as antifungal agents including polyenes, pyrimidine analogues,
echinocandins and triazoles. Polyenes such as amphotericin B have
the ability to bind ergosterol and act as a sterol “sponge” thus desta-
bilizing membrane functions (Anderson et al., 2014). Amphotericin
B exerts intrinsic toxic effects in human, however this negative
effect can be alleviated by liposome formulations (Sanglard and
Odds, 2002). Echinocandins block the catalytic subunit of the ß-1,3
glucan synthase and thus inhibit cell wall biosynthesis (Arendrup
and Perlin, 2014). Triazoles are still the mostly used antifungals.
These compounds target a speciﬁc step in ergosterol biosynthe-
sis catalysed by lanosterol 14-demethylase (Sanglard and Odds,
2002). Fluconazole is the major triazole in clinical settings, probably
due to its high oral availability and tolerability by patients.The activity of these different antifungal classes on fungal
pathogens can vary and several factors are involved in this process.
Variations of antifungal activities have different bases, including
occurrence of intrinsic or acquired resistance. Antifungal activities
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an also depend on underlying mechanisms that are related to anti-
ungal tolerance. Finally, antifungal activity can also be altered by
ersistence mechanisms. The terminology and deﬁnitions behind
hese different mechanisms is often not properly used in published
tudies. The terms “drug resistance” and “drug tolerance” are often
sed for reporting the same phenotypes, thus creating confusions.
n this review, we will attempt to more clearly deﬁne these differ-
nt terms and summarize the present knowledge on the different
echanisms that determine the activity of antifungal agents. We
ill also evaluate the impact of antifungal tolerance on the fate of
ntifungal therapy.
. What is understood by antifungal activity?
There are two basic antifungal susceptibility patterns in vitro
mong fungal pathogens. Either the presence of the antifungal drug
esults in a decrease or absence of growth capacity at a given
oncentration as compared to untreated control or the antifun-
al drug does not affect fungal growth of speciﬁc species at any
oncentrations. The absence of drug activity in a species that was
ot pre-exposed to the tested agent is also known as intrinsic
esistance. For example, it is known that wild type C. albicans is
usceptible to ﬂuconazole, whereas A. fumigatus is intrinsically
esistant to this azole (Pfaller, 2012). Several other examples of
ntrinsic resistance are given in Table 1. Antifungal activity is usu-
lly measured with standard broth dilution protocols enabling
nter-laboratory comparisons. Two major protocols are currently
sed, either originating from two major antifungal susceptibility
esting subcommittees (CLSI: Clinical Laboratory Standards Insti-
ute; EUCAST: European Committee on Antimicrobial Susceptibility
esting). The protocols yield so-called minimal inhibition concen-
ration (MIC) values (given in g/ml) as measures of antifungal
ctivity. These protocols use microtitre 96 well plates, albeit with
ell formats that are speciﬁc for each method. While these proto-
ols differ in several technical aspects, the agreement between the
wo methods in terms of antifungal activities is generally high. For
xample, MIC  values for isavuconazole in C. albicans range from ≤
able 1
verview on the activity of antifungal agents in several fungal pathogensa.
Organism Antifungal agentb
Amphotericin B Fluconazole Itraconazole Voricon
Aspergillus species
A. ﬂavus ± − + + 
A.  fumigatus + − + + 
A.  niger + − + + 
A.  terreus − − + + 
Candida species
C. albicans + + + + 
C.  glabrata + ± ± ± 
C.  krusei + − ± + 
C.  lusitaniae − + + + 
C.  parapsilosis + + + + 
C.  tropicalis + + + + 
Other species
Cryptococcus neoformans + + + + 
Coccidioides species + + + + 
Blastomyces + + + + 
Histoplasma species + + + + 
Fusarium species ± − − ± 
Scedosporium apiospermum ± − ± ± 
Scedosporium proliﬁcans − − − ± 
Zygomycetes ± − − − 
a Adapted from Ashley et al. (2006), Espinel-Ingroff (2003) and Denning and Hope (201
b Plus signs (+) indicate that the antifungal agent has activity against the speciﬁed or
gainst the speciﬁed organism. Plus-minus signs (±) indicate that the agent has different
c Adapted from data provided by Lackner et al. (2012) and Castanheira et al. (2012).nce Updates 23 (2015) 12–19 13
0.008 to 0.03 g/ml for CLSI while these values range from ≤0.008
to 0.015 g/ml for EUCAST (Pfaller et al., 2013). Variability in agree-
ments depends more on the tested fungal species (Arendrup et al.,
2013; Rambach et al., 2011). One of the major differences between
the two  methods is their incubation time (24- and 48 h for CLSI;
24 h for EUCAST) before measurement of MIC  values. Second, the
MIC  values are determined either by optical density (OD) measure-
ments with EUCAST (antifungal concentration that results in ≤50%
of decrease in OD as compared to control) or by visual inspection
with CLSI.
3. What is antifungal resistance?
Now that antifungal activity can be measured by speciﬁc proto-
cols, it is possible to determine how these activities are distributed
within a same fungal species and how these activities can be
compared with other species. When taking the distribution of ﬂu-
conazole MICs in C. albicans clinical isolates, a bell-shaped Gaussian
distribution can be observed (Fig. 1). Such distributions can be
obtained with other antifungal agents and other fungal species
(Arendrup et al., 2013). MIC  distributions can identify isolates that
are different from wild type isolates. The EUCAST deﬁnes the limit
above which non-wild type isolates can be detected as the epi-
demiological cut off (ECOFF) value. The ECOFF value is deﬁned as
the upper limit of the wild type population (Fig. 1) and can be
selected based on visual inspection (the eye ball method). Taking
Fig. 1 as an example, the ECOFF value for ﬂuconazole in C. albicans
is 1 g/ml. Above this value, isolates differ from the wild type pop-
ulation by the potential occurrence of resistance mechanism. Thus,
ECOFF values help to identity non-wild type isolates exhibiting
potential resistance mechanisms to a given drug within a given
population. Table 2 summarizes these values for several agents and
major fungal pathogens.Considering that antifungal resistance occurs in vitro above
the ECOFF values, it should be possible to identify the resistance
mechanisms prevailing in non-wild type isolates. With the help of
antifungal resistance mechanisms known for C. albicans and azoles
azole Posaconazole Anidulafungin Caspofungin Micafungin Flucytosine
+ + + + −
+ + + + −
+ + + + −
+ + + + −
+ + + + ±
± + + + ±
+ + + + −
+ + + + +
+ ± ± ± +
+ + + + +
+ − − − +
+ ± ± ± −
+ ± ± ± −
+ ± ± ± −
± − − − −
+ ±c ±c ±c −
± − − − −
± − − − −
0).
ganism. Minus signs (−) indicate that the antifungal agent does not have activity
 activities (+ and −) against the speciﬁed organism.
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Fig. 1. Distribution of ﬂuconazole MICs in C. albicans. MIC  data were obtained from
the  EUCAST MIC  Database (http://mic.eucast.org/Eucast2/SearchController/). The
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Fig. 2. Distribution of ﬂuconazole MICs in C. albicans according to occurrence of
azole resistance mechanisms. Data were obtained from data published in (Coste
T
Eell  shaped blue curve was obtained with GraphPad Prism with Log Gaussian curve
tting. Epidemiological cut off (ECOFF) and clinical breakpoint for resistance (CBP)
re indicated with corresponding values.
see for review Sanglard (2011)), we observed that, from a total
f 38 isolates, 25 contained azole resistance mechanisms inves-
igated at the molecular level and only 1 isolate without known
esistance mechanism was above the ECOFF value threshold (Fig. 2).
hree isolates with known resistance mechanism had ﬂucona-
ole MICs below this threshold. Interestingly, these three isolates
ontain each a single resistance mechanism (amino acid substi-
ution in Erg11p) with minor effect on ﬂuconazole MICs, which
ndicates that some speciﬁc azole resistance mutations might not
e correctly identiﬁed by the established ECOFF threshold. Taken
ogether, these data however strongly support the notion that the
COFF value can distinguish between wild type and non-wild type
solates.
Clinical breakpoints (CBP) should reﬂect the relationship
etween in vitro antifungal activity and the likelihood of success
r failure of therapy of a given drug. These clinical breakpoints
ere established by EUCAST and CLSI using several clinical
arameters including in vivo PK-PD, resistance mechanisms and
linical response (Table 2). Referring to Fig. 1, the EUCAST CBP for
able 2
COFF and CBP of different antifungal agents and fungal speciesa.
ECOFF (g/ml) 
Species Method Fluconazole Anidulafungin Micafu
C. albicans CLSI 0.5 ≤0.12 ≤0.03 
EUCAST  1 0.03 0.015
C.  glabrata CLSI 32 ≤0.25 ≤0.03 
EUCAST  32 0.06 0.03 
C.  parapsilosis CLSI 2 ≤4 ≤4 
EUCAST  2 4 2 
C.  tropicalis CLSI 2 ≤0.12 ≤0.12 
EUCAST  2 0.06 0.06 
C.  krusei CLSI 64 ≤0.12 ≤0.12 
EUCAST  128 0.06 0.25 
a Data obtained from published studies (Arendrup et al., 2013; Maubon et al., 2014; Pfa
b Categorical discrimination between resistant (R) and susceptible (S).
c “–” Indicates that susceptibility testing is not recommended as the species is a poor t
d “IE” indicates that there is insufﬁcient evidence that the species in question is a goodet al., 2007, 2009). CBP for resistance and ECOFF values are indicated by dotted
black and green lines, respectively. Blue and red triangles indicate MIC  values from
isolates with and without known resistance mechanisms, respectively.
ﬂuconazole in C. albicans categorizes all isolates as azole-resistant.
The isolates exhibit known azole resistance mechanisms and
one could expect that they would be refractory to azole therapy.
However, CBP can have limited predictive power. For example,
while a 92% success rate for C. albicans 550 events were observed
with ﬂuconazole MICs of ≤2 g/ml, it decreases to 83% success
among 52 events with MICs of ≥4 g/ml and drops to 37% success
among 212 events with MIC  of 8 g/ml (Pfaller, 2012). From a
fungal point of view, the relative lack of reliability of the CBP
for predicting patient outcome could be explained by the fact
that antifungal susceptibility methods have a limited capacity to
predict the response of fungal pathogens to antifungals in vivo.
4. What is antifungal tolerance?
Among the diverse characteristics contributing to the efﬁcacy
of a given drug, an important and often neglected parameter is the
ability of fungal pathogens to tolerate the presence of a drug. Drug
tolerance is deﬁned in the ﬁeld of antimicrobial agents as the ability
to withstand killing at drug concentrations above the MIC  (Fridman
et al., 2014). Antibiotic tolerance is reversible and thus is rather the
result of epigenetics as opposed to drug resistance which depends
CBP (g/ml)
ngin Fluconazole Anidulafungin Micafungin
Sb Rb S R S R
2 4 0.25 0.5 0.25 0.5
 2 4 0.03 0.03 0.016 0.016
0.002 32 0.12 0.25 0.06 0.12
0.002 32 0.06 0.06 0.03 0.03
2 4 2 4 2 4
2 4 0.002 4 0.002 2
2 4 0.25 0.5 0.25 0.5
2 4 0.06 0.06 IEd IE
–c – 0.25 0.5 0.25 0.5
– – 0.06 0.06 IE IE
ller et al., 2010, 2014).
arget for therapy with the drug.
 target for therapy with the drug.
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species in the presence of azoles at concentrations above the MIC
(Marchetti et al., 2000b; Marr et al., 1999). Trailing growth can be
more or less pronounced and mirrors the degree of azole tolerance.
Fig. 4 illustrates the different degrees of tolerance to ﬂuconazole
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Isolate 3ig. 3. Illustrations of the occurrence of antifungal resistance (upper panel) and tol
ild  type, while the dashed blue curve the behaviour of a drug-resistant isolate (u
orrespond to data of wild-type and drug-resistant (upper panel) or drug-tolerant (
n genes and their mutations. Drug tolerance can result in the pres-
nce of so-called persisters, which are dormant cells appearing
tochastically in the presence of antibiotics (Lewis, 2007). Drug
olerance is a concept that was proposed with antibacterial drugs
ossessing a cidal effect. Tolerant persisters can therefore be sim-
ly distinguished by their ability to withstand antibiotic killing
bove the MIC. The presence of persisters in bacterial bioﬁlms and
ndeed the presence of persister cells in antibiotic treatments might
e important in the aetiology of many recalcitrant infectious dis-
ases (Lewis, 2007). Recent data show that persister bacterial cells
re favoured by nutrient starvation and mechanisms that induce
ecrease in membrane potential, thus resulting in a dormant stage
Verstraeten et al., 2015).
In line with what has been published in bacteria, antifungal tol-
rance could be also deﬁned as the ability of cells to survive at drug
oncentrations that exceed the MIC. In this sense, antifungal tol-
rance is different from antifungal resistance, which itself reﬂects
n increase of MIC  value independent of the ability to survive at
rug concentrations higher than this value (Fig. 3). On the other
and, antifungal tolerance needs to be adjusted to antifungal drug
lasses containing either fungistatic (azoles) or fungicidal drugs
candins, amphotericin B). Basically, it is possible to say that fungal
athogens are generally tolerant to azoles, since fungal cells are not
illed by drug concentrations above individual MICs. However, and
his is a speciﬁcity of azoles, the degree of azole tolerance can vary
ithin a same fungal species. The degree of azole tolerance reﬂects (lower panel) in typical susceptibility tests. The red curve shows the behaviour of
anel) or a drug-tolerant isolate (lower panel). Red curves and blue hatched curves
 panel) isolates, respectively.
a phenomenon that is known as the “trailing growth” in suscepti-
bility tests. Trailing growth of speciﬁc Candida spp. with azoles has
been repeatedly reported and describes residual growth of these0
Fluconazole (µg/ml)
Fig. 4. MIC susceptibility test illustrating the different degrees of antifungal toler-
ance.
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n several C. albicans isolates. Isolate 3 shows the highest degree
f azole tolerance with a MIC  at 0.5 g/ml. Isolate 1 and 2 exhibit
ower degrees of azole tolerance as compared to isolate 3 and have
oth ﬂuconazole MIC  values between 0.0625 and 0.125 g/ml. Tak-
ng larger subsets of clinical isolates with low ﬂuconazole MICs, our
wn data show that the majority resembles proﬁles of isolates 1 and
 (D. Sanglard, unpublished). Tolerance with fungicidal agents such
s caspofungin or amphotericin B can be estimated by measuring
ell survival in MIC  tests. For example, after 24 h exposure of two  C.
labrata isolates (#4205 and #4393) to caspofungin concentration
 times above the MIC, cell survival was decreased as compared to
he incoculum in both isolates, however one isolate (#4393) sur-
ived by 2 logs CFU better than the other. Thus, isolate #4393 can be
onsidered as more tolerant to caspofungin than #4205 (Barchiesi
t al., 2005).
C. albicans bioﬁlms are known to be resistant to several anti-
ungal agents. Contrary to resistance in planktonic cells, which can
cquire resistance by genetic modiﬁcations, resistance of C. albicans
ioﬁlm cells is only a transient state. Addressing whether or not
ioﬁlms cells are resistant or tolerant to antifungal agents chal-
enges the deﬁnition of resistance and tolerance. Taking as example
he MIC  of amphotericin B in planktonic and bioﬁlm conditions, it
as been reported that the MIC  of bioﬁlm cells was 16-fold higher
han planktonic cells, thus implying that bioﬁlm formation results
n amphotericin B resistance (Tobudic et al., 2010). Above this MIC
alue, bioﬁlm cells are able to survive in the presence of ampho-
ericin B, as indicated by a recent study (Li et al., 2015a). When
dmitting that drug tolerance is the ability to survive at drug con-
entration higher than the MIC, these surviving cells are tolerant
o amphotericin B. These surviving cells can be deﬁned as persister
ells and thus persisters originate from drug tolerance mechanisms.
. The occurrence of fungal persitence
Success of antifungal therapy could be considered as the absence
f disease symptoms when therapy resumes. Endpoints quantify-
ng the success of a therapy in animal assays are often associated
ith fungal burdens in tissues and reduction of these burdens as
ompared to untreated animals. Pharmacokinetic (PK) and phar-
acodynamic (PD) parameters have been proposed to reach the
ptimal dosage which could predict the success of antifungal ther-
py. Animal model studies have determined that the ratio of the
4 h area under the concentration-time curve (AUC) divided by the
IC  (AUC/MIC) is a PD parameter that correlates best with ﬂucona-
ole efﬁcacy. Ratios of AUC/MIC between 20 and 50 can predict a
uccessful therapy (Lepak and Andes, 2014). Clinical data are less
lear about the validity of these PD parameters. Recent data for ﬂu-
onazole suggest that a ratio >400 could be more accurate to predict
ositive outcomes for C. albicans infections (Brosh-Nissimov and
en-Ami, 2015). CBP have been also proposed which could help pre-
icting the outcomes of antifungal treatments (Hope and Drusano,
009). Nevertheless, even if a therapy is considered as successful,
he fungal pathogen (a persister) may  not be totally eradicated from
ost tissues. In this case, if antifungal therapy is abandoned, relapse
f infection could occur. In animal models of fungal infections, this
spect is neglected or not addressed in the vast majority of reports.
owever, infection relapses are relevant in clinical settings. Infec-
ion relapses may  be caused by fungal persisters, which are cells
ble to survive in the host environment even after antifungal ther-
py. These cells are present in small numbers and can be hidden
rom detection in infected tissues. A recent illustrative example
rom persister cells has been given by Jacobsen et al. (2014) when
aspofungin was administered in an invasive murine model of C.
lbicans infection. The authors used in vivo imaging techniques to
eveal that a signiﬁcant portion of C. albicans cells were still presentnce Updates 23 (2015) 12–19
in the gall bladder of mice treated with this agent. The in vivo
imaging technique was crucial to enable the detection of biolu-
minescent C. albicans cells in this speciﬁc organ, which would have
been probably missed by conventional detection methods. Interest-
ingly Jacobsen et al.  (2014) discovered that bile acids present in the
gall bladder were counteracting the activity of several antifungal
agents including candins, azoles and amphotericin B. Thus, the gall
bladder could provide an optimal environment for the occurrence
of persisters in C. albicans. The basis for the formation of persisters
is still unknown. However, persisters may  form from increased tol-
erance to antifungal agents, as earlier mentioned. As in the case
of tolerance, persistence is also a reversible state and thus differs
from the occurrence of resistance which is mediated by stable gene
alterations.
Persister cells are also known as phenotypic variants of wild
type cells arising in bioﬁlms (LaFleur et al., 2006). These cells are in
a dormant state in analogy with bacterial persisters. Whether the
bioﬁlms persisters and those occurring in host tissues during anti-
fungal therapy are cells with similar features in still unknown. A
recent study has explored the tolerance mechanisms of the per-
sisters formed in a bioﬁlm and exposed to an amphotericin B
concentration above the MIC  (Li et al., 2015a). The authors used pro-
teomic proﬁles of C. albicans bioﬁlm persister fractions. Enzymes
crucial in glycolysis, tricarboxylic acid cycle and protein synthesis
were markedly decreased as compared to untreated cells, indi-
cating that major metabolic activities are kept at low levels in
persisters. The current ﬁndings suggest that a subtle metabolic con-
trol plays a role in the survival and antifungal tolerance of C. albicans
bioﬁlm persisters.
6. Mechanisms of antifungal tolerance
Tolerance mechanisms to antifungal drug have received little
attention as compared to the study of resistance mechanisms. One
of the approaches to resolve the basis for antifungal tolerance was
by the search of substances which will inhibit tolerance. Loss of tol-
erance to azoles was  ﬁrst demonstrated when cyclosporine A (CsA),
an inhibitor of calcineurin activity, was  added simultaneously to
ﬂuconazole in MIC  checkerboard tests in C. albicans (Marchetti
et al., 2000b; Sanglard et al., 2003). The construction of mutants
lacking the gene CNA/CMP1 gene encoding calcineurin subunit A
established that azole tolerance was mediated by calcineurin activ-
ity and its calcium-dependent activation pathway (Sanglard et al.,
2003). Interestingly, tolerance to other inhibitors including caspo-
fungin was  also decreased in the cna/ mutant as compared to
wild type, suggesting that calcineurin plays an important role in the
response of C. albicans to other stress generating agents (Sanglard
et al., 2003). It is important to underscore that calcineurin regulates
drug tolerance only and not drug resistance, since the presence
or absence of this activity does not alter drug susceptibility as
measured by drug susceptibility assays (Sanglard et al., 2003). Cal-
cineurin was also shown as a client protein of the chaperone Hsp90.
Inhibition of Hsp90 functions is comparable to a loss of calcineurin
activity and therefore mimic  a calcineurin mutant with respect to
drug tolerance (Cowen, 2013). It has also been shown that Hsp90
stabilizes a terminal kinase of the PKC pathway and this may  partic-
ipate to antifungal tolerance (LaFayette et al., 2010). Additionally,
Hsp90 has a buffering capacity when living cells are exposed to var-
ious insults. In yeast, Hsp90 can therefore determine the fate and
trajectory of antifungal resistance, a concept that was  addressed
and veriﬁed in S. cerevisiae (Cowen and Lindquist, 2005). Of inter-
est is that Hsp90 was  shown to undergo acetylation/deacetylation
cycles and that the state of acetylation in C. albicans could deter-
mine Hsp90 activity and chaperone activity on calcineurin (Robbins
et al., 2012). Inhibiting deacetylase activity was shown to reduce
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zole trailing growth (i.e. azole tolerance) in C. albicans, thus being
onsistent with the effect of acetylation on Hsp90 and its client
rotein calcineurin (Li et al., 2015b).
Tetracycline and its derivatives, which are antibiotics inhibi-
ing protein synthesis, were found to potentiate the activity of
uconazole in C. albicans. For example, minocycline is synergistic
ith ﬂuconazole against ﬂuconazole-resistant C. albicans isolates
Liu et al., 2014). Synergism between doxycycline (DOX), another
etracycline derivative, and ﬂuconazole has also been reported in
zole-resistant isolates (Gao et al., 2013). This conclusion was  also
eported by Fiori and van Dijck (2012) when high DOX concentra-
ions were used (>200 g/ml). This study also revealed that DOX
educed tolerance of C. albicans to ﬂuconazole. This effect was
ependent on iron availability in the culture medium, which could
e modulated by the iron-chelating ability of DOX. Interestingly,
OX had a fungicidal effect at ﬂuconazole concentrations above the
IC. Taken together, these results suggest a relationship between
ron homeostasis and antifungal tolerance.
Antifungal tolerance mechanisms can also be approached by
creening of yeast mutants in which azoles have a fungicidal effect.
or example, it was showed that a C. albicans mutant lacking the
ranscriptional activator UPC2 was killed by ﬂuconazole as opposed
o wild type (Vasicek et al., 2014). UPC2 regulates sterol homeo-
tasis in C. albicans and since azoles perturb this pathway, one
an expect dramatic effects for the fungus. The study of Vasicek
t al. (2014) showed that the UPC2 mutant became hypersuscepti-
le to azoles as measured by a MIC  decrease as compared to wild
ype. UPC2 therefore confounds effects on both azole tolerance and
esistance. A similar study but performed with C. glabrata mutants
dentiﬁed the calcium channels genes CCH1 and MID1 as critical for
uconazole tolerance, since absence of these genes converted this
zole into a fungicidal agent (Kaur et al., 2004). These data therefore
uggest a connection between calcium entry and azole tolerance.
his may  be expected since a functional calcium homeostasis is
equired for calcineurin activity, which itself is important for azole
olerance as mentioned above.
In another recent study, it was shown that a C. albicans
ps21/ mutant which is blocked in membrane trafﬁcking
hrough the late endosomal prevacuolar compartment, was able
o grow signiﬁcantly more than the wild type in the presence of
uconazole under standard susceptibility testing conditions. This
rowth behaviour resembled characteristics of trailing. Thus, VPS21
ight be a mediator of azole tolerance, however this is rather an
bsence of its activity that favours trailing. The authors of the study
peculated that vacuole biogenesis and sterol homeostasis may  be
onnected and that toxic sterols produced upon azole treatment are
edistributed to different cell compartments, which is less toxic for
he fungus (Luna-Tapia et al., 2015).
Lastly, Marr et al. (1999) showed that azole tolerance in C.
lbicans may  be dependent on pH of the culture medium. Mea-
uring azole MIC  at neutral pH resulted in trailing growth at azole
oncentration above the MIC. This phenotype was  not observed at
ow pH. These results suggest that the pH may  modulate azole tol-
rance. However, the study of Marr et al. (1999) used two different
edium compositions in which the pH was also different. While the
H hypothesis in azole tolerance is attractive, further experiments
eed to be performed in a medium-independent manner.
Tolerance mechanisms to antifungal classes different than
zoles are still poorly understood. As mentioned above the cal-
ineurin/HSP90 complex is critical for tolerance of C. albicans to
chinocandins. While echinocandins have intrinsic fungicidal activ-
ties in C. albicans, compromising calcineurin and/or HSP90 activity
ncreases to variable extent this fungicidal activity. This is consis-
ent with a role of calcineurin/HSP90 in echinocandin tolerance.
he calcineurin/HSP90 complex appears also important for toler-
nce to a wide range of growth inhibitors not only in C. albicans butnce Updates 23 (2015) 12–19 17
also in other fungal species. One issue in the identiﬁcation of novel
mediators of tolerance of non-azole antifungals is that a high num-
ber of studies report antifungal susceptibility assays which cannot
predict and measure drug tolerance. In many instances, serial dilu-
tions on agar plates containing a given drug and a given fungal
isolate are performed and can reﬂect enhanced or decreased drug
susceptibility. In order to assess drug tolerance, cell viability assays
should be performed which is mostly not the case. In some other
cases, antifungal tolerance was  correctly addressed. For example,
in a study published by Miyazaki et al. (2010), C. glabrata was
subjected to time-kill assays in the presence of micafungin. A C.
glabrata mutant lacking the protein mitogen-activated kinase gene
SLT2 was  subjected to the same assay, however this mutant was
killed 10-times more efﬁciently than the parent wild type as the
same supra-MIC drug concentration. The data thus suggested that
SLT2 was  involved in the tolerance of C. glabrata to micafungin. SLT2
is part of the so-called fungal cell wall integrity pathway in fungi.
Interestingly, SLT2 is also involved in the response of C. glabrata
to ﬂuconazole, however it is not yet clear if this gene participates
to ﬂuconazole tolerance (Schwarzmüller et al., 2014). Echinocan-
dins have been shown to stimulate this pathway in other fungi
such as C. albicans (Reinoso-Martín et al., 2003). Mutants lacking
this kinase were also shown to be more susceptible in serial dilu-
tion assays in C. albicans (LaFayette et al., 2010; Reinoso-Martín
et al., 2003). Even though, viability testing were not performed in
C. albicans, one may  suggest that the cell wall integrity pathway
is likely to be involved in echinocandin tolerance as in the case of
C. glabrata.
7. Is antifungal tolerance a favourable ground for
development of resistance?
Resistance to antifungals develops by the acquisition of muta-
tions on speciﬁc genes (Cowen et al., 2002; Sanglard and Odds,
2002). Tolerance allows a better survival of fungal pathogens at
high drug concentrations and thus the probability to obtain muta-
tions responsible for resistance under drug selective pressure might
be higher. There is still no clear evidence in the literature to sup-
port this hypothesis. Hsp90 has been reported as important in the
process of drug tolerance as above-mentioned (Cowen et al., 2014).
Studies have highlighted that Hsp90 is critical for maintaining the
capacity of C. albicans to develop resistance. Compromising Hsp90
activity in C. albicans decreases also the ability of this pathogen to
develop, in the presence of azoles, speciﬁc inactivating mutations
in the gene encoding 5,6 sterol desaturase (ERG3) (Cowen and
Lindquist, 2005). Even though Hsp90 acts on upstream and down-
stream elements which control the fate of cells in the presence of
other antifungals and growth inhibitors, the role of Hsp90 in the
development of resistance has not been yet thoroughly addressed
(Cowen, 2013).
8. Impact of drug tolerance in drug treatment efﬁcacy
When antifungal susceptibility is measured in vitro and CBP are
reached, this leads in most cases to inefﬁcacy of drug treatments in
animal experiments. For example, MacCallum et al. (2010) showed
that a C. albicans isolate with a ﬂuconazole MIC  of 64 g/ml was
not responding to ﬂuconazole treatment in a murine model of
invasive infection (Effective dose: ED50 > 200 mg ﬂuconazole/kg).
When azole resistance mechanisms related to drug efﬂux or ERG11
mutations were removed in this isolate, individual progenitors
with single resistance mechanisms were obtained and exhibited
the same ﬂuconazole MIC  (4 g/ml). The ED50 value for isolates
still containing the drug efﬂux mechanism (120 mg  ﬂuconazole/kg)
was however 10-fold higher than for the ERG11-based mechanism.
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his highlighted that, even if C. albicans isolates exhibit similar
IC  values, the outcome of therapy depends on the operating
esistance mechanism.
The effect of antifungal tolerance on the efﬁcacy of drug treat-
ent is still controversial, given the few available studies. Some
tudies revealed that the absence of tolerance to a given drug is
eneﬁcial for in vivo drug efﬁcacy. For example, when calcineurin
ctivity was inhibited by cyclosporine A in a rat endocarditis infec-
ion model with C. albicans, ﬂuconazole treatment decreased the
ungal load of some infected tissues (heart vegetations) to almost
ndetectable levels, whereas treatment with ﬂuconazole alone was
nly moderately decreasing the tissue fungal load (Marchetti et al.,
000a). The beneﬁcial effect of cyclosporine A was  due to the fact
hat ﬂuconazole is fungicidal when calcineurin activity is inhibited.
hese experiments demonstrated that the inhibition of antifungal
olerance is an interesting concept for the design of more efﬁcient
ntifungal therapy.
The effect of varying tolerance on in vivo treatment efﬁcacy is
ess clear. In a ﬁrst study, Rex et al. (1998) used a set of C. albicans
solates with high and low trailing growth characteristics in ﬂu-
onazole therapy experiments with mice. This study showed that
ne isolate with trailing growth was responding to ﬂuconazole
herapy to the same extent than another isolate without trailing
rowth. The issue in this study was that the MIC  of the trailing iso-
ate at 48 h reading was above 64 g/ml (CLSI protocol) while it
as 0.25 g/ml at 24 h reading. Thus, depending on the mode of
ndpoint reading, the in vitro susceptibility was not corresponding
o treatment outcome. The authors recommended a 24 h endpoint
eading to be coherent with animal data. Noteworthy is a study
n which the relationship between caspofungin MICs of several
andida spp. and patient outcomes was investigated. No direct
orrelation could be observed, thus suggesting that the MIC  test
ethod was not adequately reﬂecting the potential and efﬁcacy
f the drug in the patient (Kartsonis et al., 2005). Another work
ublished by Arthington-Skaggs et al. (2000) reached similar con-
lusions. This study tested two different C. albicans isolates with
uconazole trailing characteristics given the divergent endpoint
eadings at 24 and 48 h (CLSI protocol). The authors used an alter-
ative sterol quantitation method (SQM) for in vitro determination
f azole susceptibility, which measured cellular ergosterol content
ather than growth inhibition after exposure to ﬂuconazole. With
his method, both trailing isolates exhibited similar SQM MIC  values
≤1.0 g/ml). It was interesting to observe that survival of trailing
solates at a ﬂuconazole dosage of 1 mg/kg/day was  not as high
s compared to a non-trailing isolate. Second, fungal burden of
railing isolates were signiﬁcantly higher at day 3 than the other
ested non-trailing isolate (Arthington-Skaggs et al., 2000). These
ata thus suggest that the degree of tolerance (or the degree of
railing growth) can have a signiﬁcant impact on the kinetics and
uccess of therapy.
. Perspectives
While mediators of antifungal resistance have been well
escribed over the past years, still little attention was  given to
ntifungal tolerance. In this review, we ﬁrst attempted to clarify
he notion of tolerance, which is too often confounded with the
escription of drug resistance in published studies. We  think that
ntifungal tolerance is important for determining the degree of
rug efﬁcacy, however it will be necessary to revisit the relationship
etween drug tolerance and drug efﬁcacy using appropriate exper-
mental models of infection, adequate dosage and also improved
ungal cell detection tools such as live imaging. Moreover, it will
e necessary to address whether or not antifungal tolerance can
acilitate the development of resistance.nce Updates 23 (2015) 12–19
The phenomenon of azole trailing has been described for
nearly 2 decades but still no convincing molecular explanation
has been provided. In the future, antifungal tolerance should be
approached mechanistically with molecular techniques that have
been designed recently in the ﬁeld of fungal pathogens. Not only
antifungal tolerance should be addressed in C. albicans but also
in non-C. albicans species (for example C. glabrata, C. tropicalis, C.
paraspilosis) as well as in ﬁlamentous fungi such as A. fumigatus.  The
discovery of mediators of antifungal tolerance would be of inter-
est, since they might be targeted by potential inhibitors. This way,
they might increase drug efﬁcacy and ultimately may  delay the
development of resistance.
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